Abstract
Low-dose (25 mg) or very low-dose (12.5 mg) spironolactone were added among 86 uncontrolled hypertensive patients who were undergoing monotherapy with calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin AT1-receptor blockers (ARBs). Morning home systolic/diastolic blood pressure (BP) reduction was similar among the CCB (n = 30, -8.2/-2.6 mmHg), ACEI (n = 22, -13.0/-4.7 mmHg), and ARB (n = 34, -11.5/-5.1 mmHg) groups. An increase in serum potassium correlated positively with the decline in morning systolic BP. Even very low-dose (12.5 mg) spironolactone is clinically effective, although serum potassium should be carefully monitored.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Angiotensin II Type 1 Receptor Blockers / administration & dosage
-
Angiotensin-Converting Enzyme Inhibitors / administration & dosage
-
Antihypertensive Agents / administration & dosage*
-
Blood Pressure / drug effects*
-
Blood Pressure Monitoring, Ambulatory
-
Calcium Channel Blockers / administration & dosage
-
Diuretics / administration & dosage*
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Female
-
Humans
-
Hypertension / blood
-
Hypertension / drug therapy*
-
Hypertension / physiopathology*
-
Male
-
Middle Aged
-
Potassium / blood
-
Spironolactone / administration & dosage*
Substances
-
Angiotensin II Type 1 Receptor Blockers
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents
-
Calcium Channel Blockers
-
Diuretics
-
Spironolactone
-
Potassium